BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31342361)

  • 1. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.
    Sun S; van la Parra RFD; Rauch GM; Checka C; Tadros AB; Lucci A; Teshome M; Black D; Hwang RF; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
    Ann Surg Oncol; 2019 Oct; 26(10):3071-3079. PubMed ID: 31342361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.
    Sun SX; Kuerer HM
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):804-805. PubMed ID: 31654165
    [No Abstract]   [Full Text] [Related]  

  • 3. The percentage of residual DCIS in patients diagnosed with primary invasive breast cancer treated with neoadjuvant systemic therapy: A nationwide retrospective study.
    Ploumen RAW; Keymeulen KBMI; Kooreman LFS; van Kuijk SMJ; Siesling S; Smidt ML; van Nijnatten TJA
    Eur J Surg Oncol; 2022 Jan; 48(1):60-66. PubMed ID: 34756527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
    Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
    Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
    Groen EJ; van der Noordaa MEM; Schaapveld M; Sonke GS; Mann RM; van Ramshorst MS; Lips EH; Vrancken Peeters MTFD; van Duijnhoven FH; Wesseling J
    Breast Cancer Res Treat; 2021 Aug; 189(1):213-224. PubMed ID: 33945043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting breast and axillary response after neoadjuvant treatment for breast cancer: The role of histology vs receptor status.
    Vugts G; Van den Heuvel F; Maaskant-Braat AJG; Voogd AC; Van Warmerdam LJC; Nieuwenhuijzen GAP; Van der Sangen MJC
    Breast J; 2018 Nov; 24(6):894-901. PubMed ID: 30033607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M; Yau C; Symmans WF; Boughey JC; Ewing CA; Balassanian R; Chen YY; Krings G; Wallace AM; Zare S; Fadare O; Lancaster R; Wei S; Godellas CV; Tang P; Tuttle TM; Klein M; Sahoo S; Hieken TJ; Carter JM; Chen B; Ahrendt G; Tchou J; Feldman M; Tousimis E; Zeck J; Jaskowiak N; Sattar H; Naik AM; Lee MC; Rosa M; Khazai L; Rendi MH; Lang JE; Lu J; Tawfik O; Asare SM; Esserman LJ; Mukhtar RA
    JAMA Surg; 2022 Nov; 157(11):1034-1041. PubMed ID: 36069821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
    Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA
    Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis.
    Ploumen RAW; de Mooij CM; Gommers S; Keymeulen KBMI; Smidt ML; van Nijnatten TJA
    Eur Radiol; 2023 Aug; 33(8):5423-5435. PubMed ID: 37020070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis.
    Ploumen RAW; Claassens EL; Kooreman LFS; Keymeulen KBMI; van Kats MACE; Gommers S; Siesling S; van Nijnatten TJA; Smidt ML
    Breast Cancer Res Treat; 2023 Sep; 201(2):227-235. PubMed ID: 37395816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
    Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
    JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
    Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
    J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.
    Mohapatra M; Sarma YS
    J Cancer Res Ther; 2020; 16(6):1419-1425. PubMed ID: 33342807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
    Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
    Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
    Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.